Credit: Verywell / Joules Garcia
For the past several years, a seductive logic has governed the treatment of metastatic non-small cell lung cancer in patients with limited disease spread: if immunotherapy is shrinking the tumor systemically, why not hit the residual sites with radiation or surgery and finish the job? The appeal was intuitive. Local consolidative therapy (LCT) had shown benefit in the chemotherapy era. Dual checkpoint blockade was extending median survival past four years. Combining them seemed not just reasonable but almost obvious.
The LONESTAR trial just told us it isn't.
Presented at the IASLC 2026 World Conference on Lung Cancer, LONESTAR is the first phase III randomized controlled trial to directly test LCT after dual immunotherapy induction in metastatic NSCLC. The result: adding LCT to nivolumab plus ipilimumab did not improve overall survival. It did not improve progression-free survival. It didn't even help in the oligometastatic subgroup. And the HR trended in…
